A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

NCT04044209 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No patients were able to be screened nor enrolled.

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions

DRUG: AG-120
DRUG: Nivolumab

Sponsor

Yale University